Novel Approaches to Control of the Alternative Complement Pathway for the Treatment of C3 Glomerulopathies

作者
Mohamed R. Daha,Marc A. Seelen
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:29 (8): 2032-2033 被引量:2
标识
DOI:10.1681/asn.2018050554
摘要

The complement system is an important pillar of our innate and acquired immune system, and it is essential for host defense against foreign pathogens. Activation of complement has important functions that, in general, are beneficial to the host, but when adverse complement activation occurs by or near our own tissue and cells, the same functions can become detrimental to the host. In general, complement activation is under strict control by a number of fluid phase– and tissue-associated complement regulators. Complement can be activated by three known pathways, namely the classic pathway, the lectin pathway, and the alternative pathway. After initial complement activation by any of these pathways, further amplification is essential for efficient elimination of foreign pathogens, unwanted cell debris, and soluble immune complexes and for triggering of the common effector pathway with activation of C5 and generation of the membrane attack complex (MAC) C5b-9. The degree of amplification of C3 activation in the fluid phase is controlled to an important degree by complement factor H (CFH). CFH is a 155-kD glycoprotein that consists of 20 short consensus repeats. Short consensus repeats 18–20 bind to cell surfaces and recognize C3b. CFH controls complement activation in both the fluid- and tissue-associated phases; because it can bind to cells (for instance, endothelial cells), it conveys extra protection to complement-mediated injury. Uncontrolled C3 activation occurs in C3 glomerulopathy (C3G), and treatment options for C3G are limited. Some progress has been made with the treatment of C3G with eculuzimab, an mAb against C5 that prevents the generation of the phlogistic fragment C5a from C5 and the formation of the MAC; however, the success of treatment is often uncertain. In this issue of the Journal of the American Society of Nephrology, Wang et al.1 explored the potential efficacy of an Fc fusion protein of complement receptor of the Ig superfamily (CRIg-Fc) in the treatment of mice with an experimental form of C3G, namely mice with a common CFH and properdin double deficiency. These mice develop an early onset of C3G with increased C3 catabolism, increased proteinuria, and lethal crescentic GN. Treatment of the double-deficient mice with CRIg-Fc but not the control Fc fusion protein reduced proteinuria, hematuria, BUN, C3 deposition, and GN scores. Additionally, treatment with CRIg-Fc improved complement pathology and survival. Treatment of these mice was started at 4 weeks of age, at which time the mice have a mild form of C3G. The question remains whether CRIg-Fc will prove to be efficient in reversal of a fully active disease. The findings, however, are promising, and combined with the fact that it down modulates the degree of C3 amplification, it adds a potential new approach to the treatment of C3G in patients. Other promising approaches are being explored. Like the approach of using CRIg-Fc as a down modulator of C3 amplification, two other inhibitors have been developed. Both are on the basis of the regulatory domains of CFH itself. Yang et al.2 engineered two CFH miniconstructs consisting of specific domains of CFH, with a higher retention of the drug in the kidneys of mice. These mini-CFH constructs were fully able to regulate complement amplification in mice, and they were shown to be very effective in prevention of glomerular C3 deposition in CFH-deficient mice. The advantage of using these CFH miniconstructs is that they block complement activation in the affected organ directly, whereas the CRIg-Fc mainly down modulates circulating complement activation. Another very promising agent to block the alternative pathway convertase was reported recently by Michelfelder et al.3 They synthesized a fusion protein MFHR1 that contains the regulatory domains of CFH and the C5 convertase/C5b-9 inhibitory fragment of FH-related protein 1. MFHR1 has cofactor and decay accelerating activity and inhibits C5 convertase activation and MAC assembly, which prevent C3b deposition. Administration of MFHR1 to CFH−/− mice resulted in inhibition of C3 activation in vivo and reduced abnormal C3 deposition in the kidneys. The advantage of MFHR1 is that it not only controls alternative pathway C3 activation but that it also affects the C5 convertase and generation of MAC. The idea to down modulate complement activation at the C3 level was introduced quite a number of years ago by the research group of Lambris and colleagues.4 They developed a drug called Compstatin that prevents C3 activation by binding to C3 itself. Continuous development of the Compstatin scaffold for increased target affinity, inhibitory efficacy, and advantageous pharmacokinetic properties has resulted in the analog CP40, which also looks very promising in preclinical models of C3G and other complement-mediated diseases. In summary, several potentially very promising drugs that control the degree of the activity of the alternative pathway are now in the pipeline. Most of these drugs are still in the preclinical stage, and much more work is ahead to bring these drugs to implementation in the clinic. Disclosures None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Owen的应助被xiahaijun采纳,获得20
刚刚
半月完成签到 ,获得积分10
1秒前
1秒前
99668完成签到,获得积分0
2秒前
郭郭郭完成签到,获得积分10
2秒前
嘟嘟嘟嘟嘟完成签到,获得积分10
2秒前
唐唐完成签到 ,获得积分10
3秒前
延渊发布了新的文献求助10
4秒前
耶耶完成签到,获得积分10
7秒前
8秒前
辛勤的喉发布了新的文献求助30
8秒前
Eric_Zhou完成签到,获得积分10
9秒前
濮阳灵竹完成签到,获得积分10
9秒前
爆米花的应助被彭铭渌采纳,获得10
10秒前
QAQ完成签到,获得积分10
10秒前
iuiu666完成签到 ,获得积分10
12秒前
正直凡灵发布了新的文献求助10
12秒前
感动谷冬完成签到 ,获得积分20
12秒前
呆萌的青烟完成签到,获得积分10
12秒前
科研通AI6.2的应助被刘K采纳,获得30
12秒前
13秒前
块块的加隆满口袋完成签到,获得积分10
13秒前
我是谁的应助被科研通管家采纳,获得150
13秒前
kk子的应助被科研通管家采纳,获得10
14秒前
香蕉觅云的应助被科研通管家采纳,获得10
14秒前
jokerli完成签到,获得积分10
14秒前
sagitar的应助被科研通管家采纳,获得40
14秒前
NexusExplorer的应助被科研通管家采纳,获得10
14秒前
斯文败类的应助被科研通管家采纳,获得10
14秒前
14秒前
14秒前
Owen的应助被科研通管家采纳,获得10
14秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
14秒前
ding的应助被科研通管家采纳,获得10
15秒前
赘婿的应助被科研通管家采纳,获得10
15秒前
婉孝完成签到,获得积分10
15秒前
大个的应助被科研通管家采纳,获得10
15秒前
华仔的应助被科研通管家采纳,获得10
15秒前
李爱国的应助被科研通管家采纳,获得10
15秒前
共享精神的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190410
求助须知:如何正确求助?哪些是违规求助? 9577638
关于积分的说明 21853499
捐赠科研通 7789404
什么是DOI,文献DOI怎么找? 3436395
关于科研通互助平台的介绍 2560220
邀请新用户注册赠送积分活动 2483032